[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:oropharyngeal-squamous-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":255,"states":264},"Oropharyngeal Squamous Cell Carcinoma",40,37,[8,16,22,28,34,40,46,52,58,64,71,78,84,90,96,102,108,114,120,126,132,137,144,150,156,163,169,175,181,187,193,199,205,211,217,223,229,235,242,248],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06448026","Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma",[12],"Phase 2","RECRUITING","2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.754376Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05317000","5-Azacytidine and\u002For Nivolumab in Resectable HPV-Associated HNSCC",[12],"2026-08-26T02:15:18.897219Z","2026-06-17T02:29:29.995073Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07513389","Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)",[12],"2026-08-26T02:17:45.190188Z","2026-05-29T15:36:40.194242Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT05268614","Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.512737Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06223568","Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer",[12],"2026-08-03T03:13:22.003666Z","2026-05-05T02:43:29.471790Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT06088381","Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)",[12],"2026-08-26T02:18:26.932189Z","2026-05-05T02:43:29.296327Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT05419089","The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)",[12],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.852988Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":56,"content_modified":57},"NCT06323460","Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:28.846466Z",{"nct_id":59,"title":60,"phases":61,"status":13,"updated_at":62,"content_modified":63},"NCT05541016","De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.485078Z",{"nct_id":65,"title":66,"phases":67,"status":13,"updated_at":69,"content_modified":70},"NCT06747390","Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery",[68],"Phase 1","2026-08-26T02:17:56.243868Z","2026-05-05T02:43:28.192617Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":76,"content_modified":77},"NCT06563479","A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer",[75],"Phase 3","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.989005Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07044635","Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.806024Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06915038","ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx",[],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.757826Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT03875716","Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma",[],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:27.669935Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05962242","HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.631667Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07172256","CUE-101with Pembrolizumab for LA-HPV+HNSCCs",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:27.601527Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT04852328","Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma",[12],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.932385Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT04900623","Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study",[12],"2026-08-26T02:16:00.194860Z","2026-05-05T02:35:31.906438Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT07497607","Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:15:47.754948Z","2026-04-29T02:57:57.100938Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06477692","Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:28.102992Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":94,"content_modified":136},"NCT07227792","Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer",[],"2026-05-05T02:43:26.935506Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":142,"content_modified":143},"NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",[141],"Phase 1\u002FPhase 2","2026-08-26T02:17:33.002248Z","2026-07-05T05:32:16.809101Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT02734537","Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:27.925178Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT04671667","Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:17:24.721169Z","2026-05-05T02:43:26.694944Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":161,"content_modified":162},"NCT06914999","Comparing an Investigational Scan (F-18 NaF PET\u002FCT) to Standard of Care Imaging (F-18 FDG PET\u002FCT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer",[160],"Early Phase 1","2026-08-26T02:18:30.351130Z","2026-05-05T02:43:29.497806Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06413355","FAPI-74 PET\u002FCT in Adults With Fibrosis",[68],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:29.397681Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT07179315","A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment",[12],"2026-08-26T02:16:04.914942Z","2026-07-19T19:36:05.138967Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06115772","Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study",[],"2026-08-26T02:19:19.975067Z","2026-05-13T02:55:06.420134Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT05862792","Liposomal Bupivacaine and Transoral Robotic Surgery",[],"2026-08-26T02:15:22.311223Z","2026-05-13T02:55:06.389460Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05600842","De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx",[],"2026-08-26T02:17:16.980188Z","2026-05-13T02:55:06.364729Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT04564989","Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC",[],"2026-08-26T02:18:57.189473Z","2026-05-13T02:55:06.254087Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06356272","Oropharynx (OPX) Biomarker Trial",[],"2026-08-26T02:15:10.362237Z","2026-05-13T02:55:06.483201Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT06174428","Validity of Viome's Oral\u002Fthroat Cancer Test",[],"2026-08-26T02:15:01.639696Z","2026-05-13T02:55:06.421318Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT06055868","People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity",[],"2026-08-26T02:17:09.131534Z","2026-05-13T02:55:06.405251Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT05451303","Detection of Oral and Throat Cancers Using OralViome Cancer Testing System",[],"2026-08-26T02:18:43.501109Z","2026-05-13T02:55:06.349144Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06494111","Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline\u002FTocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)",[12],"2026-08-26T02:19:21.761002Z","2026-05-05T02:43:27.504712Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06532279","Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer",[12],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:28.872744Z",{"nct_id":236,"title":237,"phases":238,"status":239,"updated_at":240,"content_modified":241},"NCT07513324","Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.871423Z",{"nct_id":243,"title":244,"phases":245,"status":239,"updated_at":246,"content_modified":247},"NCT07428148","Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma",[141],"2026-08-26T02:19:05.360997Z","2026-04-29T02:57:57.115905Z",{"nct_id":249,"title":250,"phases":251,"status":252,"updated_at":253,"content_modified":254},"NCT04858269","First Line Weekly Chemo\u002FImmunotherapy for Metastatic Head\u002FNeck Squamous Cell Carcinoma Patients",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:38:34.966507Z","2026-05-05T02:43:27.981907Z",[256,260],{"biomarker":257,"count":258,"slug":259},"CDKN2A wt Allele",18,"cdkn2a-wt-allele",{"biomarker":261,"count":262,"slug":263},"HPV",14,"hpv",[265,269,272,275,278,282,285,289,292,295,298,301,304,307,311,314,317,320,323,327,330,333,336,339],{"state":266,"count":267,"slug":268},"Florida",7,"florida",{"state":270,"count":267,"slug":271},"Minnesota","minnesota",{"state":273,"count":267,"slug":274},"New York","new-york",{"state":276,"count":267,"slug":277},"Pennsylvania","pennsylvania",{"state":279,"count":280,"slug":281},"Massachusetts",6,"massachusetts",{"state":283,"count":280,"slug":284},"South Carolina","south-carolina",{"state":286,"count":287,"slug":288},"California",5,"california",{"state":290,"count":287,"slug":291},"Connecticut","connecticut",{"state":293,"count":287,"slug":294},"Maryland","maryland",{"state":296,"count":287,"slug":297},"Missouri","missouri",{"state":299,"count":287,"slug":300},"New Jersey","new-jersey",{"state":302,"count":287,"slug":303},"North Carolina","north-carolina",{"state":305,"count":287,"slug":306},"Ohio","ohio",{"state":308,"count":309,"slug":310},"Illinois",4,"illinois",{"state":312,"count":309,"slug":313},"Indiana","indiana",{"state":315,"count":309,"slug":316},"Tennessee","tennessee",{"state":318,"count":309,"slug":319},"Texas","texas",{"state":321,"count":309,"slug":322},"Virginia","virginia",{"state":324,"count":325,"slug":326},"Arizona",3,"arizona",{"state":328,"count":325,"slug":329},"Arkansas","arkansas",{"state":331,"count":325,"slug":332},"District of Columbia","district-of-columbia",{"state":334,"count":325,"slug":335},"Georgia","georgia",{"state":337,"count":325,"slug":338},"Iowa","iowa",{"state":340,"count":325,"slug":341},"Kansas","kansas"]